This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Michael J. Fox Foundation Announces Fourth Quarter Participants In Partnering Program Between Awardees And Industry

NEW YORK, Nov. 15, 2012 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation (MJFF) has announced fourth-quarter 2012 participants in its Partnering Program. Selected from the most promising research projects in the MJFF portfolio, Partnering Program participants' research projects are presented directly to industry groups who may wish to invest in further development of the project. By connecting industry leaders with those projects ripe for investment, the Foundation aims to drive forward promising projects in PD research through the pipeline of drug development, and eventually into patients' hands.

Non-confidential overviews of select MJFF-funded projects are shared with industry contacts and more broadly via MJFF's Web site on a quarterly basis.

MJFF-supported projects featured in Q4 include:

  • SynAgile is developing DopaFuse, a levodopa prodrug which is continuously, subcutaneously infused using a simple insulin infusion pump.  It is designed to reduce motor fluctuations in people with PD.
  • Durin Technologies has completed work to determine if using specific autoantibodies as diagnostic biomarkers for full-blown Parkinson's could also be used for early detection of PD.
  • Sapiens is working on technology to more accurately stimulate intended therapeutic brain structures in Deep Brain Stimulation, toward improving therapeutic outcomes and reducing side effects for Parkinson's patients. 

Overviews from awardees PsychoGenics and Gliacor Therapeutics were showcased in Q3 2012.

To date, the Foundation has funded over $304 million in research, over $81 million of which has been directed to more than 170 unique projects led by industry partners.

To view the Q4 2012 participants, and all MJFF awardees featured via the Partnering Program thus far, visit the Partnering Program page at  https://www.michaeljfox.org/research/opportunities-for-industry/partnering-program.html.

To find out more, please contact the MJFF Research Partnerships team at ResearchPartnerships@michaeljfox.org.

SOURCE The Michael J. Fox Foundation

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,041.54 -190.48 -1.04%
S&P 500 2,104.20 -21.86 -1.03%
NASDAQ 5,032.7510 -56.6110 -1.11%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs